NGAL is a Precocious Marker of Therapeutic Response

Author(s): Valeria Cernaro, Davide Bolignano, Valentina Donato, Antonio Lacquaniti, Antoine Buemi, Eleonora Crascì, Silvia Lucisano, Michele Buemi.

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 8 , 2011

Submit Manuscript
Submit Proposal

Abstract:

NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.

Keywords: NGAL, acute renal failure, chronic kidney disease, clinical nephrology, clinical pharmacology, glomerulonephritis, vasculitis, antimicrobial, gentamicin, microalbuminuria, Crohn's disease, flogistic, Infliximab, idiopathic, streptozotocin, angiotensin, sepsis, inefficacy, etiologic, immunosuppressors

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 8
Year: 2011
Page: [844 - 849]
Pages: 6
DOI: 10.2174/138161211795428939
Price: $58

Article Metrics

PDF: 5